PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D
Solid Tumor|TNBC - Triple-Negative Breast Cancer
COMBINATION_PRODUCT: LAE005 + Afuresertib + Nab-Paclitaxel
To evaluate the safety., Frequency and severity of AEs (including incidence rate of DLTs)., 1year|recommended Phase II dose (RP2D) of LAE005 and afuresertib and nab-paclitaxel as a combination treatment in patients with advanced solid tumours (including mTNBC), Frequency and severity of AEs (including incidence rate of DLTs)., 1year|To evaluate the tolerability., Frequency and severity of AEs (including incidence rate of DLTs)., 1year|To determine the maximum tolerated dose (MTD), Frequency and severity of AEs (including incidence rate of DLTs)., 1year
To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via DCR, Disease Control Rate (DCR) base on RECIST 1.1;, 1 year|To characterize the AUC0-t of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel., Plasma concentrations and PK parameters of LAE005 and afuresertib, AUC0-t of afuresertib following combination treatment, calculated from PK samples obtained at various time points., 1 year|To characterize the AUC0-inf of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel., Plasma concentrations and PK parameters of LAE005 and afuresertib, AUC0-inf of afuresertib following combination treatment, calculated from PK samples obtained at various time points., 1 year|To characterize the Tmax of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel., Plasma concentrations and PK parameters of LAE005 and afuresertib, Tmax of afuresertib following combination treatment, calculated from PK samples obtained at various time points., 1 year|To characterize the T1/2 of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel., Plasma concentrations and PK parameters of LAE005 and afuresertib, T1/2 of afuresertib following combination treatment, calculated from PK samples obtained at various time points., 1 year|To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via BOR, Best Overall Response Rate (BOR) base on RECIST 1.1;, 1 year|To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via DOR, Duration of Response (DOR) base on RECIST 1.1;, 1 year|To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via PFS, Progression-Free Survival (PFS) base on RECIST 1.1;, 1 year
Phase I dose escalation for triple combination therapy with BOINcomb design,The safety (including DLT), tolerability, and PK are the study endpoints of phase I and to determine MTD and RP2D.